Lyell Immunopharma (LYEL) – Investment Analysts’ Weekly Ratings Changes

Lyell Immunopharma (NASDAQ: LYEL) has recently received a number of price target changes and ratings updates:

• 6/9/2026 – Lyell Immunopharma had its “market outperform” rating reaffirmed by Citigroup Inc..
• 6/9/2026 – Lyell Immunopharma had its “buy” rating reaffirmed by HC Wainwright. They now have a $45.00 price target on the stock.
• 6/8/2026 – Lyell Immunopharma had its “buy” rating reaffirmed by Needham & Company LLC. They now have a $44.00 price target on the stock.
• 6/3/2026 – Lyell Immunopharma was given a new $45.00 price target by Needham & Company LLC.
• 6/3/2026 – Lyell Immunopharma had its “buy” rating reaffirmed by HC Wainwright. They now have a $45.00 price target on the stock.
• 5/18/2026 – Lyell Immunopharma was upgraded by Zacks Research from “strong sell” to “hold”.
• 5/10/2026 – Lyell Immunopharma was upgraded by Wall Street Zen from “sell” to “hold”.
• 5/7/2026 – Lyell Immunopharma had its “buy” rating reaffirmed by Needham & Company LLC. They now have a $44.00 price target on the stock.
• 5/2/2026 – Lyell Immunopharma was downgraded by Wall Street Zen from “hold” to “sell”.
• 4/30/2026 – Lyell Immunopharma was given a new $49.00 price target by Robert W. Baird. They now have an “outperform” rating on the stock.
• 4/30/2026 – Lyell Immunopharma was upgraded by Robert W. Baird to “strong-buy”.
• 4/21/2026 – Lyell Immunopharma had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 4/18/2026 – Lyell Immunopharma was upgraded by Wall Street Zen from “sell” to “hold”.

Lyell Immunopharma is a clinical-stage biotechnology company focused on developing next-generation T cell therapies for cancer. Leveraging a proprietary platform that combines cell therapy, gene editing and molecular discovery, Lyell seeks to overcome key barriers in the treatment of solid tumors. The company’s approach centers on engineering T cells to enhance their persistence, functionality and resistance to the immunosuppressive tumor microenvironment.

The company’s pipeline includes multiple autologous T cell programs engineered to target tumor-associated antigens in solid malignancies such as melanoma, ovarian and pancreatic cancers.